Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Jan;77(1):3-17.
doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Josef S Smolen  1   2 , Monika Schöls  3 , Jürgen Braun  4 , Maxime Dougados  5 , Oliver FitzGerald  6 , Dafna D Gladman  7 , Arthur Kavanaugh  8 , Robert Landewé  9 , Philip Mease  10 , Joachim Sieper  11 , Tanja Stamm  12 , Maarten de Wit  13 , Daniel Aletaha  1 , Xenofon Baraliakos  4 , Neil Betteridge  14 , Filip van den Bosch  15 , Laura C Coates  16 , Paul Emery  17 , Lianne S Gensler  18 , Laure Gossec  19 , Philip Helliwell  20 , Merryn Jongkees  21 , Tore K Kvien  22 , Robert D Inman  23 , Iain B McInnes  24 , Mara Maccarone  25 , Pedro M Machado  26 , Anna Molto  5 , Alexis Ogdie  27 , Denis Poddubnyy  11   28 , Christopher Ritchlin  29 , Martin Rudwaleit  11   30 , Adrian Tanew  31 , Bing Thio  32 , Douglas Veale  33 , Kurt de Vlam  34 , Désirée van der Heijde  35
Affiliations
Practice Guideline

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Josef S Smolen et al. Ann Rheum Dis. 2018 Jan.

Erratum in

Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Keywords: Ankylosing Spondylitis; Outcomes Research; Psoriatic Arthritis; Spondyloarthritis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DA served as a consultant and/or speaker for Abbvie, Astra-Zeneca, BMS, Janssen, Medac, MSD, Pfizer, Roche, UCB and received grant support from BMS. XB has served as consultant and/or speaker for Abbvie, BMS, Celgene, Chugai, Janssen, Novartis, Pfizer, UCB. NB has received consultancy fees for work commissioned by Grünenthal, Lilly, Janssen, PfizerLaura Coates has received research funding from Abbvie and Janssen and honoraria from Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Sun Pharma, UCBMaxime Dougados has participated as a speaker in symposia or as an advisor in boards organized by Pfizer, Abbvie, Ucb, Merck, Amgen, Novartis, Lilly, Bms, Roche and his department has received research grants from Pfizer, Abbvie, Ucb, Merck, Amgen, Novartis, Lilly, Bms, Roche. Laure Gossec has received honoraria or research funding from Abbvie, BMS, Celgene, Janseen, MSD, Novartis, Pfizer, Roche and UCB. PE has undertaken clinical trials and provided expert advice to Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. OF reports grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Lilly, personal fees from Cellgene, grants and personal fees from Abbvie, personal fees from Janssen, personal fees from UCB, outside the submitted work. AK has served as consultant and/or performed clinical research for Abbvie, Amgen, Celgene, Janssen, Novartis, UCB. PMM has received consultancy/speaker’s fees from AbbVie, Centocor, Janssen, Merck, Novartis, Pfizer and UCB. AM has received honoraria from Abbvie, MSD and UCBDP has received Grant/research support from: AbbVie, MSD, Novartis, Pfizer, has honoraria/speaker fees from AbbVie, BMS, Boehringer, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB. MR has received honoraria/ consultancies from Abbvie, BMS, Celgene, Chugai/Roche, Janssen, MSD, Novartis, Pfizer, UCB. JS has received grant support from and/or provided expert advice to Abbvie, Amgen, Astra-Zeneca, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Gilead, Glaxo, Iltoo, Janssen, Lilly, Pfizer, MSD, Roche, Samsung, Novartis-Sandoz, UCB. TS has received honoraria from Abbvie, Janssen, MSD, Novartis and Roche and grant support from Abbvie. FVB has received speaker and/or consultancy fees from AbbVie, Celgene, Janssen,Lilly, MSD, Novartis, Pfizer and UCB. DH has received consulting fees Afrom bbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, and is Director of Imaging Rheumatology bv. MW has received consulting fees for lectures or advisory board meetings from Abbvie, BMS, Celgene, Eli Lilly, Novartis and Roche.

Figures

Figure 1
Figure 1
Relationships between inflammation, damage and disability. Inflammation, by virtue of pain and stiffness, elicits disability which is reversible on reversal of disease activity. Inflammation also induces damage which is usually irreversible. Damage also induces disability; due to its irreversible nature, damage-induced disability is irreversible, meaning that with increasing damage the floor of physical functioning that can be reached on reversal of disease activity rises.
Figure 2
Figure 2
Algorithm based on the 2017 update of the treat-to-target recommendations for spondyloarthritis. axSpA, axial SpA; CRP, C-reactive protein; DAPSA, Disease Activity index for PSoriatic Arthritis; MDA, Minimal Disease Activity; PsA, psoriatic arthritis; SpA, spondyloarthritis.
See this image and copyright information in PMC

Comment in

References

    1. Smolen JS, Braun J, Dougados M, et al. . Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16. 10.1136/annrheumdis-2013-203419 - DOI - PMC - PubMed
    1. Gossec L, Smolen JS, Ramiro S, et al. . European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510. 10.1136/annrheumdis-2015-208337 - DOI - PubMed
    1. Coates LC, Kavanaugh A, Mease PJ, et al. . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060–71. 10.1002/art.39573 - DOI - PubMed
    1. van der Heijde D, Ramiro S, Landewé R, et al. . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. 10.1136/annrheumdis-2016-210770 - DOI - PubMed
    1. Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1305–6. 10.1056/NEJM199505113321915 - DOI - PubMed

Publication types